Equities Analysts Offer Predictions for COGT Q3 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT) – Analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Cogent Biosciences in a research note issued on Wednesday, August 19th. HC Wainwright analyst R. Burns now expects that the technology company will post earnings per share of ($0.59) for the quarter, down from their prior estimate of ($0.56). HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for Cogent Biosciences’ Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.37) EPS.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings data on Monday, August 10th. The technology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.03.

A number of other research firms also recently weighed in on COGT. Piper Sandler upped their price target on Cogent Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Cogent Biosciences in a report on Wednesday, July 8th. Guggenheim upped their target price on Cogent Biosciences from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Finally, Wedbush reiterated an “outperform” rating and issued a $55.00 target price on shares of Cogent Biosciences in a report on Friday, May 29th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.40.

Cogent Biosciences Stock Performance

Shares of COGT opened at $35.31 on Friday. Cogent Biosciences has a one year low of $11.60 and a one year high of $43.73. The company has a market cap of $6.13 billion, a PE ratio of -16.35 and a beta of 0.38. The stock has a 50-day moving average of $38.42 and a 200-day moving average of $36.63. The company has a debt-to-equity ratio of 0.48, a current ratio of 13.57 and a quick ratio of 13.57.

Hedge Funds Weigh In On Cogent Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC raised its stake in shares of Cogent Biosciences by 482.6% in the first quarter. AQR Capital Management LLC now owns 160,767 shares of the technology company’s stock worth $963,000 after purchasing an additional 133,174 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Cogent Biosciences by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,275 shares of the technology company’s stock worth $377,000 after buying an additional 3,693 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Cogent Biosciences by 14.3% during the first quarter. Goldman Sachs Group Inc. now owns 988,962 shares of the technology company’s stock worth $5,924,000 after buying an additional 124,069 shares in the last quarter. Jane Street Group LLC raised its position in Cogent Biosciences by 66.2% in the 1st quarter. Jane Street Group LLC now owns 123,822 shares of the technology company’s stock valued at $742,000 after buying an additional 49,338 shares during the last quarter. Finally, Strs Ohio purchased a new stake in Cogent Biosciences in the 1st quarter valued at $36,000.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.